An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin

G. S. Markowitz, G. A. Kahn, Robert E. Feingold, Maria Coco, R. I. Lynn

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Iron balance is critical for adequate erythropoiesis in hemodialysis patients treated with recombinant human erythropoietin (EPO). The role of oral iron therapy in maintaining or replenishing iron stores has not yet been well defined in such patients. We undertook a double-blind, placebo-controlled study to evaluate the efficacy of oral iron in 49 hemodialysis patients, divided into two groups, based on adequate or deficient iron stores. These groups were treated for 3 months with 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals) or placebo, twice daily. Laboratory parameters were followed for five months. These parameters included: hematocrit (Hct), ferritin, transferrin saturation (Tsat), and zinc protoporphyrin (ZPP). A side-effects questionnaire was recorded monthly. Our results indicate that iron replete patients show evidence of falling iron stores during the study period; this observation was identical in both oral iron and placebo subgroups. Iron deficient patients had a significantly greater drop-out rate due to side effects when compared to iron replete patients (33% vs. 8%), despite equivalent responses to the side-effect questionnaire. We conclude: 1) Oral iron fails to maintain iron stores in iron replete patients; 2) Iron deficiency observed in this study may be due to poor medication compliance rather than side-effects.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalClinical Nephrology
Volume48
Issue number1
StatePublished - 1997

Fingerprint

Erythropoietin
Renal Dialysis
Iron
Therapeutics
Placebos
Medication Adherence
Erythropoiesis
Transferrin
Ferritins
Hematocrit
Polysaccharides

Keywords

  • Erythropoietin
  • Hemodialysis
  • Iron polysaccharide-complex (Niferex)
  • Oral iron
  • Zinc protoporphyrin (ZPP)

ASJC Scopus subject areas

  • Nephrology

Cite this

An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. / Markowitz, G. S.; Kahn, G. A.; Feingold, Robert E.; Coco, Maria; Lynn, R. I.

In: Clinical Nephrology, Vol. 48, No. 1, 1997, p. 34-40.

Research output: Contribution to journalArticle

@article{59bf470a67dd42e6b475db29a634ce10,
title = "An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin",
abstract = "Iron balance is critical for adequate erythropoiesis in hemodialysis patients treated with recombinant human erythropoietin (EPO). The role of oral iron therapy in maintaining or replenishing iron stores has not yet been well defined in such patients. We undertook a double-blind, placebo-controlled study to evaluate the efficacy of oral iron in 49 hemodialysis patients, divided into two groups, based on adequate or deficient iron stores. These groups were treated for 3 months with 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals) or placebo, twice daily. Laboratory parameters were followed for five months. These parameters included: hematocrit (Hct), ferritin, transferrin saturation (Tsat), and zinc protoporphyrin (ZPP). A side-effects questionnaire was recorded monthly. Our results indicate that iron replete patients show evidence of falling iron stores during the study period; this observation was identical in both oral iron and placebo subgroups. Iron deficient patients had a significantly greater drop-out rate due to side effects when compared to iron replete patients (33{\%} vs. 8{\%}), despite equivalent responses to the side-effect questionnaire. We conclude: 1) Oral iron fails to maintain iron stores in iron replete patients; 2) Iron deficiency observed in this study may be due to poor medication compliance rather than side-effects.",
keywords = "Erythropoietin, Hemodialysis, Iron polysaccharide-complex (Niferex), Oral iron, Zinc protoporphyrin (ZPP)",
author = "Markowitz, {G. S.} and Kahn, {G. A.} and Feingold, {Robert E.} and Maria Coco and Lynn, {R. I.}",
year = "1997",
language = "English (US)",
volume = "48",
pages = "34--40",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "1",

}

TY - JOUR

T1 - An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin

AU - Markowitz, G. S.

AU - Kahn, G. A.

AU - Feingold, Robert E.

AU - Coco, Maria

AU - Lynn, R. I.

PY - 1997

Y1 - 1997

N2 - Iron balance is critical for adequate erythropoiesis in hemodialysis patients treated with recombinant human erythropoietin (EPO). The role of oral iron therapy in maintaining or replenishing iron stores has not yet been well defined in such patients. We undertook a double-blind, placebo-controlled study to evaluate the efficacy of oral iron in 49 hemodialysis patients, divided into two groups, based on adequate or deficient iron stores. These groups were treated for 3 months with 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals) or placebo, twice daily. Laboratory parameters were followed for five months. These parameters included: hematocrit (Hct), ferritin, transferrin saturation (Tsat), and zinc protoporphyrin (ZPP). A side-effects questionnaire was recorded monthly. Our results indicate that iron replete patients show evidence of falling iron stores during the study period; this observation was identical in both oral iron and placebo subgroups. Iron deficient patients had a significantly greater drop-out rate due to side effects when compared to iron replete patients (33% vs. 8%), despite equivalent responses to the side-effect questionnaire. We conclude: 1) Oral iron fails to maintain iron stores in iron replete patients; 2) Iron deficiency observed in this study may be due to poor medication compliance rather than side-effects.

AB - Iron balance is critical for adequate erythropoiesis in hemodialysis patients treated with recombinant human erythropoietin (EPO). The role of oral iron therapy in maintaining or replenishing iron stores has not yet been well defined in such patients. We undertook a double-blind, placebo-controlled study to evaluate the efficacy of oral iron in 49 hemodialysis patients, divided into two groups, based on adequate or deficient iron stores. These groups were treated for 3 months with 150 mg elemental iron (Polysaccharide complex, Central Pharmaceuticals) or placebo, twice daily. Laboratory parameters were followed for five months. These parameters included: hematocrit (Hct), ferritin, transferrin saturation (Tsat), and zinc protoporphyrin (ZPP). A side-effects questionnaire was recorded monthly. Our results indicate that iron replete patients show evidence of falling iron stores during the study period; this observation was identical in both oral iron and placebo subgroups. Iron deficient patients had a significantly greater drop-out rate due to side effects when compared to iron replete patients (33% vs. 8%), despite equivalent responses to the side-effect questionnaire. We conclude: 1) Oral iron fails to maintain iron stores in iron replete patients; 2) Iron deficiency observed in this study may be due to poor medication compliance rather than side-effects.

KW - Erythropoietin

KW - Hemodialysis

KW - Iron polysaccharide-complex (Niferex)

KW - Oral iron

KW - Zinc protoporphyrin (ZPP)

UR - http://www.scopus.com/inward/record.url?scp=0030859097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030859097&partnerID=8YFLogxK

M3 - Article

C2 - 9247776

AN - SCOPUS:0030859097

VL - 48

SP - 34

EP - 40

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 1

ER -